Filtered By:
Condition: Chronic Pain
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 178 results found since Jan 2013.
Biotech behind promising Covid vaccine pivots to veterinary medicine, spins off two divisions
Akston Biosciences Corporation is set to focus on drugs for animals, including insulin for dogs and cats, a cancer drug for dogs and a chronic pain drug for dogs.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 17, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
Fight Aging! Newsletter, July 10th 2023
In conclusion, the examination of the GBA can aid in understanding the etiology and development of NDs, which may benefit the improvement of clinical treatments for these disorders and ND interventions. This review indicates existing knowledge about the involvement of microbiota present in the gut in NDs and potential treatment options.
The Aging of the Enteric Nervous System
https://www.fightaging.org/archives/2023/07/the-aging-of-the-enteric-nervous-system/
The enteric nervous system is the nervous system of the intestines, and likely an important part of the relationship between the gut microbiome a...
Source: Fight Aging! - July 9, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, June 5th 2023
In conclusion, higher BMR might reduce lifespan. The underlying pathways linking to major causes of death and relevant interventions warrant further investigation.
Betting Against Progress Turns Out Poorly, But Can Work in the Short Term in a Slow Field
https://www.fightaging.org/archives/2023/06/betting-against-progress-turns-out-poorly-but-can-work-in-the-short-term-in-a-slow-field/
Setting oneself up as a spokesperson for "we will not achieve this goal", as the fellow noted here is choosing to do, is a bet against technological progress. A glance at any few decade period in the past two hundred year...
Source: Fight Aging! - June 4, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Fight Aging! Newsletter, May 1st 2023
In conclusion, frailty progression accelerates in males with one LTCs and females with two LTCs or more. Health providers should be aware of planning a suitable intervention once the elderly have two or more health conditions.
Plasma Transfer Lowers Epigenetic Age and Mortality in Rats
https://www.fightaging.org/archives/2023/04/plasma-transfer-lowers-epigenetic-age-and-mortality-in-rats/
Plasma transfer from young to old individuals has produced mixed results in animals and little to no benefit in humans where assessed rigorously. These studies were driven by the hypothesis that young plasma contains me...
Source: Fight Aging! - April 30, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Update on IMBRUVICA ® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U.S. indications for IMBRUVICA® (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA), c...
Source: Johnson and Johnson - April 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
People who catch Omicron are less likely to get Long Covid
Ever since the COVID-19 pandemic unfurled across the United Kingdom, hematologist John Willan has worried about the disease’s toll on his patients. In March 2020, Willan, who works at the University of Oxford and Wexham Park Hospital, began to track the hospital’s COVID-19 cases among people with leukemias, lymphomas, and other blood diseases. He counted not just the dozens of deaths, but also persistent and disabling symptoms collectively called Long Covid, which have plagued millions over the past 3 years.
These days, Willan is less anxious. After Omicron began spreading in late 2021, COVID-19 deaths became a ra...
Source: Science of Aging Knowledge Environment - March 21, 2023 Category: Geriatrics Source Type: research
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Long Waits, Short Appointments, Huge Bills: U.S. Health Care Is Causing Patient Burnout
You haven’t been feeling well lately. You’re more tired than usual, a bit sluggish. You wonder if there’s something wrong with your diet. Or maybe you’re anemic? You call your primary-care doctor’s office to schedule an appointment. They inform you the next available appointment is in three weeks.
So, you wait.
And then you wait some more.
And then, when you arrive on the day of your appointment, you wait even more.
You fill out the mountain of required paperwork, but the doctor still isn’t ready to see you. You flip through a magazine for a while, then scroll through your phone unt...
Source: TIME: Health - February 27, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized feature healthscienceclimate Magazine medicine Source Type: news
Fight Aging! Newsletter, January 16th 2023
Conclusions
Implanted Hair Follicle Cells Produce Remodeling of Scar Tissue
Assessment of Somatic Mosaicism as a Biomarker of Aging
The Gut Microbiome of Centenarians
https://www.fightaging.org/archives/2023/01/the-gut-microbiome-of-centenarians/
The state of the gut microbiome is arguably as influential on health as exercise. Various microbial species present in the gut produce beneficial metabolites, such as butyrate, or harmful metabolites, such as isoamylamine, or can provoke chronic inflammation in a variety of ways. An individual can have a better or worse microbiome, assessing these and other fu...
Source: Fight Aging! - January 15, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, January 2nd 2023
In conclusion, circulating monocytes in older adults exhibit increased expression of activation, adhesion, and migration markers, but decreased expression of co-inhibitory molecules.
MERTK Inhibition Increases Bone Density via Increased Osteoblast Activity
https://www.fightaging.org/archives/2022/12/mertk-inhibition-increases-bone-density-via-increased-osteoblast-activity/
Bone density results from the balance of constant activity on the part of osteoblasts and osteoclasts, the former building bone, the latter breaking it down. With advancing age, the balance of activity shifts to favor osteoclasts, prod...
Source: Fight Aging! - January 1, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
A Look Back at 2022: Progress Towards the Treatment of Aging as a Medical Condition
At the end of 2022, we can reflect on the fact that we are steadily entering a new era of medicine, one in which mechanisms of aging are targeted rather than ignored. It is a profound change, one that will change the shape of a human life and ultimately the human condition by eliminating the greatest sources of suffering and death in the world. Year after year, we see increased funding, ongoing progress towards therapies capable of slowing aging or reversing aspects of aging, and a growing taxonomy of such potential therapies and their target mechanisms.
The view of aging in the medical community and public at large...
Source: Fight Aging! - December 30, 2022 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs
Long COVID Has Contributed to More Than 3,500 U.S. Deaths
Long COVID—a condition with symptoms ranging from respiratory to neurological, from crushing fatigue to chronic pain—can be debilitating. And in some cases, according to a new report from the National Center for Health Statistics (NCHS), Long COVID may even be fatal.
From January 2020 through June 2022, Long COVID contributed to more than 3,500 deaths in the U.S., according to death-certificate data analyzed by NCHS researchers. About 0.3% of death certificates that listed COVID-19 as an underlying or contributing cause of death also mentioned Long COVID, for an age-adjusted death rate of 6.3 per 1 million peop...
Source: TIME: Health - December 14, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
